For example, anti-programmed death protein 1 (PD-1) monoclonal antibodies are exceptional for PD-1 receptor inhibition, thereby promoting anti-tumor CD8+ T cell activity (Hellmann et al., 2019; Hellmann and Ramalingam, 2020). This evidence concerns the gene PDCD1 and neoplasm.